Aethlon Medical, Inc. (OTCMKTS:AEMD) Stopped In Its Tracks

[[tagnumber 0]][[tagnumber 1]]The stock of Aethlon Medical, Inc. (OTCMKTS:AEMD) was one of those that benefited from the widespread ebola epidemic that has gained major attention internationally and while other penny stock contenders that wanted to get in on the hype quickly subsided, the ticker kept its run in the beginning of the week.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]The main reason for this was the news that the company’s [[tagnumber 6]]Hemopurifier [[tagnumber 7]]is used for the treatment of a patient for the first time. A Ugandan doctor who contracted the virus while working in Sierra Leone is being treated with the device in the [[tagnumber 6]]Frankfurt University Hospital[[tagnumber 7]] in Germany.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]There are still no results and it is unknown if the device works. [[tagnumber 6]]AEMD [[tagnumber 7]]has stated that they will inform us about the outcome as soon as possible. Meanwhile, however, a quick look in their balance sheet shows that the company isn’t doing that well financial–wise.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]Here is what [[tagnumber 6]]AEMD [[tagnumber 7]]reported to the SEC for the period ended June 30.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 25]] [[tagnumber 26]]cash: $807 thousand[[tagnumber 27]] [[tagnumber 26]]current assets: $938 thousand[[tagnumber 27]] [[tagnumber 26]]total assets: $1.14 million[[tagnumber 27]] [[tagnumber 26]]current liabilities; $3.66 million[[tagnumber 27]] [[tagnumber 26]]total liabilities: $4.66 million[[tagnumber 27]] [[tagnumber 26]]quarterly revenues: $51,296[[tagnumber 27]] [[tagnumber 26]]quarterly net loss: $3.65 million[[tagnumber 27]] [[tagnumber 40]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]As you can see the revenues that the company is making from government contracts isn’t nearly enough to cover for AEMD’s spending. And while [[tagnumber 6]]SeeThruEquity [[tagnumber 7]]raised the target price of [[tagnumber 6]]AEMD [[tagnumber 7]]to $0.52 per share after a collaboration with the [[tagnumber 6]]Boston University CTE Center[[tagnumber 7]] things didn’t go exactly as planned in yesterday’session.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]][[tagnumber 6]]AEMD [[tagnumber 7]]gapped up at $0.2788 and quickly rose to a high of $0.307. The massive trading of stock that took place right after the opening bell, however, quickly pushed the price down and by the end of the day [[tagnumber 6]]AEMD [[tagnumber 7]]was sitting 1.84% lower from the previous session, at a closing price of $0.24, with a total of 10.9 million traded shares and a dollar volume of $2.78 million.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]Today, the ticker is also hesitating so it would be in your best interest to do your due diligence and weigh out the risks before making an investment decision.[[tagnumber 2]]